Better Biomarker Decisions, Earlier in Development

	Drug Discovery
	The latest drug discovery news from News Medical

Spear Bio's custom assay development services combine the highest sensitivity with the lowest sample volume, enabling detection of ultra-low-abundance biomarkers while preserving precious clinical samples.

Using clinical samples earlier in development helps optimize assay configurations based on biological and analytical performance, reducing rework, accelerating development, and increasing the probability of success.

Start Your Assay Development

[Free Webinar] Revealing Proteome Diversity with timsTOF: From Single-Cell Heterogeneity to Non-Canonical Biology Content Body

A central challenge in precision cardiology is accounting for cellular heterogeneity — and single-cell proteomics is now revealing variability within cardiomyocytes that reshapes our understanding of cardiac architecture, drug response, and disease progression.

Join Jennifer Van Eyk and Nikolai Slavov as they share new findings on cardiomyocyte subpopulations in heart failure and single-cell approaches uncovering the protein dynamics underlying cardiac disease.

Book Your Place

Streamlining AI-driven drug discovery with cell-free expression and SPR

AI-driven drug discovery can be accelerated by combining cell-free expression with purification-free SPR for faster biomolecular interaction analysis.

	OutSee awarded Innovate UK grant for agentic AI pilot study to enhance drug target validation OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive approach to uncover new drug targets, today announced it has been awarded funding through Innovate UK's Investor Partnership Grant, jointly provided by Innovate UK and Empirical Ventures.

	Characterizing subvisible particles in biopharmaceuticals Explore the newest analytical approaches for identifying subvisible particles in biologic drug formulations.

	Researchers mine cobra toxins to uncover a membrane-disrupting antimicrobial peptide Researchers combined toxin sequence mining with machine learning and deep-learning prediction tools to identify and experimentally test 14 antimicrobial peptide candidates derived from cobra cardiotoxins. Most candidates showed limited antibacterial potency, while CTX-p5 displayed moderate membrane-disrupting activity, revealing both the potential and current limitations of computationally guided venom peptide discovery.

	Could scorpion venom inspire new treatments for liver disease? Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.

	New Platform Promises Rapid Vaccine Monitoring and Biomarker Discovery for Emerging Pathogens A research team comprising Associate Professor FUNAKOSHI Yohei, Associate Professor YAKUSHIJIN Kimikazu, Professor MINAMI Hironobu, and Associate Professor OHJI Goh of Kobe University, together with graduate student MASUDA Genki, then-graduate student IIZUMI Shunsuke, Associate Professor OHUE Masahito, and colleagues at the Institute of Science Tokyo, has developed a new analysis method, LM-QASAS.

How would you rate today's newsletter?

Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney

Copyright © 2000-2026